How to Sell a Medical Device Manufacturing Business (2026): ISO 13485, FDA 21 CFR 820, 510(k), and the 8-12x EBITDA Premium

Selling a medical device manufacturing business in 2026 is a fundamentally different transaction than selling any other lower middle market manufacturing business. Medical device M&A is shaped by the regulatory framework (ISO 13485 + FDA 21 CFR 820 QSR + 510(k) or PMA pathway), named medical OEM customer relationships (Medtronic, Johnson & Johnson MedTech, Stryker, Boston Scientific, Abbott, Becton Dickinson, Edwards Lifesciences, Zimmer Biomet, Thermo Fisher), Class I / II / III device tiers, validated programs with FDA-registered tooling and qualified processes, and a deeply specialized buyer pool of medical device PE platforms that have built sector expertise over multiple fund vintages. Multiples are higher than aerospace, the diligence rigor is the most demanding in any sub-vertical, and the preparation horizon is among the longest in any manufacturing segment.

This guide is for medical device manufacturing owners running between $5M and $150M of revenue, with normalized earnings between $750K SDE and $20M EBITDA. We’ll walk through the regulatory framework (ISO 13485, FDA 21 CFR 820, 510(k) vs PMA pathways, Class I / II / III tiers), DMR / DHF / CAPA system requirements, named medical OEM customer landscape, Class II disposables vs Class III implantable economics, the active medical device PE platforms (Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax Group, Wynnchurch Industrial, Riverside Company), public-company strategic acquirer pool, supply chain complexity (the medical device global supply chain that PE buyers obsess over), workforce considerations, and the 24-36 month preparation playbook that materially improves outcomes.

The framework draws on direct work with 76+ active U.S. lower middle market buyers, including 38 manufacturing-focused platforms with explicit medical device theses. We’re a buy-side partner. The buyers pay us when a deal closes — not you. That includes medical device specialty PE (Linden Capital Partners with multiple medical device platforms, Patient Square Capital with medical device thesis, LaSalle Capital, Audax Group with medical / industrial portfolio, Wynnchurch Capital industrial including medical adjacencies, Riverside Company medical specialty platforms, Genstar Capital medical, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe medical, plus 15+ medical device consolidators), public-company strategic acquirers and Tier 1 medical device contract manufacturers, family offices with medical / healthcare theses, and aerospace-experienced search funders increasingly targeting medical device. The point isn’t to convince you to sell — it’s to give you an honest read on what selling a medical device manufacturing business actually looks like in 2026.

One realistic note before you start. Medical device manufacturing has unprecedented structural tailwinds in 2026. Demographic aging drives sustained demand for orthopedic implants, cardiovascular devices, and chronic disease management products. Drug delivery (auto-injectors, on-body devices, combination products) is the fastest-growing medical device segment. Diagnostic devices (point-of-care, home testing) demand is structural. Surgical robotics adoption (Intuitive Surgical da Vinci, Medtronic Hugo, Stryker Mako, J&J Velys) drives associated component manufacturing. Reshoring of medical device supply chain (Inflation Reduction Act incentives, post-pandemic supply chain repositioning) creates new platform opportunities. The right medical device manufacturer in the right segment with the right regulatory stack is among the most acquirable lower middle market businesses in the U.S. right now — if positioned correctly. The wrong positioning — or unaddressed FDA inspection findings, regulatory gaps, customer concentration, or supply chain risk — can compress multiple by 2-4x EBITDA.

“Medical device contract manufacturing is the highest-multiple segment in lower middle market manufacturing because the regulatory moat is genuinely deep. Customers can’t move work without re-validation, FDA notifications, supplier requalification, and PPAP-equivalent submissions — processes that take 12-24 months and cost $200-700K per program. PE buyers pay 9-11x EBITDA because the revenue durability is structurally unlike anything else they underwrite.”

Key Takeaways

• Medical device manufacturing multiples by tier and certification: sub-$1M EBITDA medical = 5-7x EBITDA; $1M-$3M EBITDA ISO 13485 + FDA-aligned = 7-9x EBITDA; $3M+ EBITDA Class II disposables specialist = 8-10x EBITDA; $3M+ EBITDA Class III implantable specialist = 10-13x EBITDA. Highest-multiple segment in lower middle market manufacturing.
• Active PE platforms in 2026: Linden Capital Partners (dedicated medical device specialty with multiple platforms), Patient Square Capital (medical device thesis), LaSalle Capital, Audax Group (medical / industrial), Wynnchurch Capital industrial, Riverside Company medical specialty, Genstar Capital medical, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe medical, plus 15+ medical device consolidators.
• Regulatory framework: ISO 13485 (medical device QMS, 12-18 months to certify, $50-150K), FDA 21 CFR Part 820 (Quality System Regulation, QSR — design controls, DMR, DHF, CAPA, complaint handling), 510(k) clearances vs PMA pathway, Class I / II / III device tiers. EU MDR (Medical Device Regulation) for European market access. RoHS, REACH, biocompatibility per ISO 10993 series.
• Named medical OEM customers: Medtronic, Johnson & Johnson MedTech, Stryker, Boston Scientific, Abbott, Becton Dickinson, Edwards Lifesciences, Zimmer Biomet, Thermo Fisher Scientific, Baxter International, Smith & Nephew, Olympus. Long-validated programs (FDA-registered tooling, validated processes) carry high switching cost.
• Class II disposables (surgical instruments, infusion, drug delivery, diagnostics) is the largest contract manufacturer segment. Class III implantables (orthopedic, cardiovascular, neurological) command highest multiples. Combination devices and drug delivery are the fastest-growing segments in 2026.
• Customer concentration norms: medical 30-40% on top customer is acceptable with FDA-validated programs (long-validated programs carry high switching cost); regulatory diligence focus is FDA inspection history (Form 483 observations, warning letters, consent decrees) more than customer concentration.

Why medical device manufacturing M&A commands premium multiples

Medical device manufacturing trades at among the highest multiples of any lower middle market manufacturing sub-vertical — meaningfully higher than aerospace at platform scale. Five drivers create the premium: (1) regulatory moat is structural — ISO 13485, FDA 21 CFR 820 QSR, 510(k) / PMA pathway take years to build and customers can’t easily move validated programs; (2) named OEM customer programs are long-tenured (10-20 year programs typical) with extreme switching cost (re-validation, FDA notifications, supplier requalification); (3) demographic tailwinds (aging population) drive sustained demand for chronic disease management, orthopedics, cardiovascular, neurological devices; (4) reshoring incentives (Inflation Reduction Act, supply chain security) drive new platform formation; (5) drug delivery / combination device segment is the fastest-growing area of the medical device industry. PE buyers pay 9-11x EBITDA because they expect to exit at 10-14x in 4-5 years.

PE buyer theses are medical-device-specialty. Linden Capital Partners is among the most active dedicated medical device PE firms in the U.S., with multiple platform investments across contract manufacturing, components, and specialty medical. Patient Square Capital has a medical device thesis. LaSalle Capital invests in medical device contract manufacturing. Audax Group has medical / industrial portfolio investments including medical device. Wynnchurch Capital industrial portfolio includes medical adjacencies. Riverside Company has medical specialty platforms. Genstar Capital has medical investments. Frazier Healthcare Partners is a healthcare-dedicated PE firm. Welsh Carson Anderson & Stowe has medical investments. The specialty PE pool is deep and competitive.

Public-company strategic acquirers and Tier 1 contract manufacturers add bidder competition. Tier 1 medical device contract manufacturers (Integer Holdings on NYSE: ITGR, Phillips Medisize / Molex / Koch Industries, West Pharmaceutical Services on NYSE: WST, Heraeus Medical, Resonetics, Cretex Medical, Nordson Medical, Carlisle Medical) actively acquire smaller medical device manufacturers for capability extension and customer access. Direct medical OEM strategic acquirers (Medtronic, J&J MedTech, Stryker, Boston Scientific, Abbott) acquire upstream contract manufacturers occasionally for vertical integration.

What this means for medical device manufacturing sellers. If you have ISO 13485 + FDA 21 CFR 820 QSR-aligned operations, FDA-registered tooling, named medical OEM customer relationships, validated programs across multiple device tiers, and clean FDA inspection history, you’re in the highest-multiple lower middle market manufacturing segment in the U.S. right now. The buyer pool is competitive, with both medical device specialty PE and Tier 1 contract manufacturers actively bidding. Run a real auction process to capture the multiple; do not accept the first IOI.

The regulatory framework: ISO 13485, FDA 21 CFR 820 (QSR), 510(k), PMA, and Class I/II/III tiers

The medical device regulatory framework is the most rigorous in any manufacturing sub-vertical and is also the moat that drives premium multiples. Three layered systems govern medical device manufacturing in the U.S.: (1) ISO 13485 is the international medical device quality management system standard, providing the QMS structure for medical device design, manufacture, and post-market surveillance; (2) FDA 21 CFR Part 820 (Quality System Regulation, QSR) is the U.S. federal regulation governing medical device manufacturers — effectively overlapping but technically distinct from ISO 13485; (3) FDA premarket pathway determines how a device gets to market: 510(k) substantial equivalence pathway for most Class II devices, PMA (Premarket Approval) for Class III devices, De Novo pathway for novel low-risk devices.

ISO 13485 economics. ISO 13485 certification typically takes 12-18 months from kickoff to first registered audit and costs $50-150K including consultant support, internal training, gap remediation, surveillance audits (annual), and triennial recertification. The certification itself isn’t enough — you need 12-24 months of certified operating history with FDA-registered programs to credibly position as a medical device specialty contract manufacturer. ISO 13485 is the baseline buyers expect; the regulatory differentiation comes from FDA 21 CFR 820 QSR alignment depth, FDA inspection history, and customer-specific qualifications.

FDA 21 CFR Part 820 (QSR) and the documentation stack. FDA 21 CFR 820 imposes specific requirements: design controls (820.30) including design history file (DHF) for each device; document controls (820.40); identification and traceability (820.60, 820.65); production and process controls (820.70); device master record (DMR) for each device (820.181); device history record (DHR) for each lot/batch (820.184); CAPA system (820.100); complaint handling (820.198); servicing (820.200). Buyers diligence this documentation rigorously: DMRs by device, DHFs by program, CAPA log, complaint log, validation documentation.

510(k) vs PMA pathway and Class I/II/III tiers. Class I devices (low-risk, ~36% of medical devices) typically need only general controls; most are exempt from premarket review. Class II devices (moderate-risk, ~46% of medical devices) require 510(k) substantial equivalence clearance; this is the largest segment for contract manufacturers, including surgical instruments, infusion components, drug delivery, diagnostic disposables, hospital beds. Class III devices (high-risk, ~10% of medical devices) require PMA (Premarket Approval, the most rigorous pathway); this includes most implantable devices like orthopedic implants, cardiovascular implants, neurological implants. Contract manufacturers with documented Class III experience trade at premium because the regulatory complexity is materially higher.

FDA inspection history and Form 483 observations. FDA conducts unannounced inspections of registered medical device facilities. Findings are documented on FDA Form 483 (Inspectional Observations). Significant or recurring findings can escalate to Warning Letters, Consent Decrees, Import Alerts, or Seizure Actions. Buyers diligence FDA inspection history rigorously: every Form 483 observation in past 5 years, every Warning Letter, every CAPA opened in response, every regulatory commitment made to FDA. Open FDA matters can re-trade or kill deals. Maintaining clean inspection history through close is non-negotiable.

EU MDR, ISO 14971, ISO 10993, and global regulatory layer. EU MDR (Medical Device Regulation, EU 2017/745, fully effective 2021-2024) governs European market access. ISO 14971 (medical device risk management) overlays the QMS. ISO 10993 series governs biocompatibility testing for materials in patient contact. Country-specific approvals (Health Canada MDL, Japan PMDA, Brazil ANVISA, China NMPA) overlay U.S. and EU. Multi-region regulatory presence is a multiple-driver for contract manufacturers serving global OEMs.

Named medical OEM customers and the contract manufacturer landscape

Named medical OEM customer relationships drive multiples in medical device M&A more than any other variable except regulatory scope. The named OEMs that PE buyers and strategic acquirers care about: Medtronic (largest medical device company globally, with cardiovascular, diabetes, neuroscience, medical surgical divisions), Johnson & Johnson MedTech (formerly J&J Medical Devices, with surgical, orthopedic, vision, interventional solutions), Stryker (orthopedic implants, neurotechnology, surgical equipment, MedSurg), Boston Scientific (cardiovascular, peripheral interventions, endoscopy, urology, neuromodulation), Abbott Laboratories (cardiovascular devices, diabetes, diagnostics, neuromodulation), Becton Dickinson (BD, drug delivery, diagnostics, surgical), Edwards Lifesciences (heart valve, critical care monitoring), Zimmer Biomet (orthopedic implants), Thermo Fisher Scientific (life sciences and diagnostic systems), Baxter International (medical products, renal therapy, biopharmaceutical), Smith & Nephew (orthopedics, sports medicine, advanced wound management), Olympus (endoscopy, surgical), Hologic (women’s health, diagnostics), Dexcom (continuous glucose monitoring), Insulet (insulin pumps), ResMed (sleep / respiratory).

Contract manufacturer landscape and Tier 1 / Tier 2 / Tier 3. Tier 1 medical device contract manufacturers (typically $500M-$5B+ revenue): Integer Holdings, Phillips Medisize / Molex / Koch, West Pharmaceutical Services, Heraeus Medical, Resonetics, Cretex Medical, Nordson Medical, Carlisle Medical, Donatelle Plastics, Tessy Plastics, Plasti-World, MedTec, Sussex IM. Tier 2 contract manufacturers ($50-500M revenue) typically serve multiple medical OEMs across multiple programs. Tier 3 contract manufacturers (sub-$50M revenue) are typically specialty (specific component category, specific OEM relationship, specific manufacturing capability). Lower middle market medical device M&A primarily occurs at Tier 2 and Tier 3 levels.

How buyers diligence customer relationships in medical device. Customer interviews with top 5-10 customers (typically 60-90 minutes each, with the buyer asking about supplier performance, quality, on-time delivery, validated program tenure, growth potential, regulatory standing). Long-term agreement (LTA) and master supply agreement review — multi-year contracts are common in medical device. Program-by-program revenue analysis (which Medtronic device, which J&J device, which Stryker device). FDA-registered tooling count and validation status by program. Customer-specific quality metrics (PPM, on-time delivery, supplier scorecards, supplier audit performance). Medical OEM supplier qualification programs (Medtronic Supplier Excellence, J&J supplier qualification, Stryker supplier qualification, etc.).

Customer concentration norms in medical device. Customer concentration above 30-40% on a single medical OEM customer is common in medical device contract manufacturing and not necessarily a discount driver if the program portfolio with that customer is diversified across multiple devices and validated programs are long-tenured. Medical OEM switching cost is genuinely high (re-validation, FDA notifications, supplier requalification, PPAP-equivalent submissions, biocompatibility re-testing for materials changes), so concentrated relationships often endure for 10-20 years. Buyers price medical device concentration based on program-level diversification and validated-program tenure more than customer-level concentration.

Who actually buys medical device manufacturing businesses in 2026: the five archetypes

The medical device manufacturing buyer pool is the deepest and most competitive in lower middle market manufacturing. Five archetypes dominate. Knowing which fits your business is the highest-leverage positioning decision.

Archetype 1: Medical device specialty PE platforms. Linden Capital Partners (most active dedicated medical device PE in U.S. with multiple platforms across contract manufacturing, components, and specialty medical), Patient Square Capital (dedicated healthcare PE with medical device thesis), LaSalle Capital, Audax Group (medical / industrial portfolio), Wynnchurch Capital industrial (medical adjacencies), Riverside Company (medical specialty platforms), Genstar Capital, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe (medical investments). Typical target: $2M-$30M EBITDA with ISO 13485 + FDA 21 CFR 820 QSR-aligned operations, named medical OEM relationships, validated programs across multiple device tiers, clean FDA inspection history, and second-tier management. Multiples: 8-12x EBITDA on platform deals; 7-9x on bolt-ons. Cash + 15-30% rollover + earnout. Close timeline: 90-150 days.

Archetype 2: Tier 1 medical device contract manufacturer strategic acquirers. Integer Holdings (NYSE: ITGR, large Tier 1 medical device contract manufacturer with consolidator strategy), Phillips Medisize / Molex / Koch Industries, West Pharmaceutical Services (NYSE: WST, drug delivery and packaging), Heraeus Medical, Resonetics (laser and precision micro-component specialty), Cretex Medical, Nordson Medical, Carlisle Medical, Donatelle Plastics, Tessy Plastics, Sussex IM. These Tier 1s actively acquire Tier 2 and Tier 3 medical device contract manufacturers for capability extension, customer access, geographic coverage, or specialty positioning. Multiples: 8-12x EBITDA at platform scale, often paid with cash and a smaller rollover component than PE rollups. Close timeline: 90-180 days.

Archetype 3: Direct medical OEM strategic acquirers (occasional vertical integration). Medical OEMs (Medtronic, J&J MedTech, Stryker, Boston Scientific, Abbott, BD, Edwards Lifesciences, Zimmer Biomet) occasionally acquire upstream contract manufacturers for vertical integration, particularly when the contract manufacturer has unique capability or holds key Class III device manufacturing capacity. Multiples: 9-13x EBITDA when the strategic fit is strong. Close timeline: 120-180 days. Less frequent than PE platform or Tier 1 contract manufacturer acquisitions.

Archetype 4: Medical device regional consolidators. Smaller PE-backed medical device consolidators acquiring sub-platform-scale medical device shops in geographic clusters (Twin Cities medical device alley, Boston medical device cluster, Southern California, North Carolina Research Triangle, Salt Lake City) or by capability segment (precision injection molding for medical, complex machining, surgical instruments, electronic assemblies). Typical target: $1M-$5M EBITDA. Multiples: 7-9x EBITDA. Close timeline: 90-150 days.

Archetype 5: Search funders, family offices, and SBA individuals. Medical-experienced searchers (often former Medtronic, J&J, Stryker, BD program managers transitioning to ownership) targeting $1M-$3M EBITDA medical device contract manufacturers. Multiples: 6-8x EBITDA. Family offices with healthcare / medical theses pursuing $2M-$10M EBITDA shops. SBA-financed individuals targeting sub-$1M SDE medical device contract manufacturers. Multiples: 5-7x SDE. Close timeline: 60-180 days.

Realistic medical device manufacturing multiples by size and tier: 2026 deal data

Medical device manufacturing multiples cluster by Class tier, certification scope, and customer base far more than by raw size. A $2M EBITDA Class III implantable specialist with PMA-pathway customers outprices a $4M EBITDA Class I / II generalist contract manufacturer. Tier of devices manufactured is the primary multiple driver.

Sub-$1M SDE medical contract manufacturer (no ISO 13485): 4-5.5x SDE. Generic precision manufacturing occasionally serving medical. Buyer pool: SBA individuals primarily. Multiples compress because the seller can’t credibly position as a medical device specialty without ISO 13485.

Sub-$1M SDE ISO 13485 medical contract manufacturer: 5-7x SDE. ISO 13485 certification + FDA 21 CFR 820 QSR alignment + named medical OEM exposure (even smaller-scale Tier 3 work) shifts multiple meaningfully. Buyer pool widens to medical-experienced search funders, regional consolidators, and SBA buyers transitioning from larger medical device companies.

$1M-$3M EBITDA ISO 13485 + FDA-aligned medical: 7-9x EBITDA. Search funder, regional consolidator, and medical device specialty PE bolt-on territory. Multiples improve with: (a) FDA 21 CFR 820 QSR audit history clean; (b) named medical OEM relationships (Medtronic, J&J MedTech, Stryker, BD); (c) multi-year LTAs; (d) modern equipment and cleanroom capability; (e) second-tier management depth.

$3M+ EBITDA Class II disposables specialist: 8-10x EBITDA. Medical device specialty PE platform territory (Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax, Wynnchurch Industrial, Riverside Company). Class II disposables (surgical instruments, infusion components, drug delivery, diagnostic disposables, hospital beds, dental devices) is the largest contract manufacturer segment. Multiples premium for diversified medical OEM customer base, multi-year program portfolios, modern cleanroom capability, and growth runway.

$3M+ EBITDA Class III implantable specialist: 10-13x EBITDA. Highest-multiple lower middle market medical device segment. Class III implantables (orthopedic implants for Stryker / Zimmer Biomet / J&J / Smith & Nephew, cardiovascular implants for Medtronic / Abbott / Boston Scientific / Edwards Lifesciences, neurological implants for Medtronic / Boston Scientific / Abbott Neuromodulation) command premium driven by PMA-pathway regulatory complexity and limited PMA-experienced buyer pool. Documented Class III experience with PMA-pathway customers is genuinely scarce.

Drug delivery and combination devices: structural premium. Drug delivery (auto-injectors for Eli Lilly / Novo Nordisk / Sanofi, on-body devices, infusion pumps for Insulet / Tandem / Medtronic Diabetes, inhalers for Teva / Cipla) and combination devices command premium given high-growth segment dynamics. Contract manufacturers with documented combination-device experience trade at the high end of medical device multiples.

Class I, II, III device tiers: how the tier mix affects the multiple

FDA classifies medical devices into three risk-based tiers, and the tier mix of devices you manufacture drives the multiple ceiling. Class I devices (low-risk, ~36% of medical devices) typically need only general controls; most are exempt from premarket review. Examples: tongue depressors, bandages, manual surgical instruments. Class II devices (moderate-risk, ~46% of medical devices) require 510(k) substantial equivalence clearance. Examples: surgical instruments, infusion pumps, diagnostic disposables, hospital beds, powered medical equipment, orthopedic non-implantable hardware. Class III devices (high-risk, ~10% of medical devices) require Premarket Approval (PMA), the most rigorous regulatory pathway. Examples: cardiac pacemakers, defibrillators, heart valves, orthopedic implants, neurological implants.

Class I-only contract manufacturers: 6-8x EBITDA. Class I-only manufacturers are typically generalist medical contract manufacturers without specialty positioning. Lower regulatory complexity but also lower customer switching cost. Buyer pool overlaps with general industrial contract manufacturers but with medical-end-market positioning premium.

Class I + II contract manufacturers: 7-9x EBITDA. The largest segment of medical device contract manufacturers. 510(k)-cleared devices include surgical instruments, infusion components, drug delivery (non-combination), diagnostic disposables, hospital beds. Buyer pool is broad: medical specialty PE (Linden Capital, Patient Square, LaSalle, Audax, Wynnchurch Industrial, Riverside) plus Tier 1 medical contract manufacturer strategics (Integer, Phillips Medisize, West, Heraeus, Resonetics, Cretex).

Class III implantable manufacturers: 10-13x EBITDA. PMA pathway is materially more complex than 510(k): clinical data requirements, design controls more rigorous, biocompatibility testing more comprehensive (ISO 10993 series), manufacturing process validation more extensive. Contract manufacturers with documented Class III implantable experience are scarce — the workforce, equipment, and quality system requirements take 5-10 years to build. Premium reflects the regulatory moat and supply scarcity.

Combination devices and drug delivery: structural premium. Combination devices (drug + device, like auto-injectors, inhalers, drug-coated implants) require dual regulatory pathway (FDA CDER for drug + FDA CDRH for device) and command premium because of the regulatory and operational complexity. Drug delivery is the fastest-growing medical device segment in 2026, with auto-injectors (semaglutide / GLP-1 driven demand), on-body devices (insulin delivery, hormone delivery), and combination devices driving sustained demand. Drug delivery contract manufacturers trade at 9-12x EBITDA.

Why Class III experience is hard to fake. Class III contract manufacturing requires PMA-pathway-validated processes, documented design controls per FDA 21 CFR 820.30, biocompatibility testing per ISO 10993 series, sterilization validation, packaging validation, and clinical-batch manufacturing capability. The infrastructure takes years and tens of millions of dollars to build. Contract manufacturers can’t reposition Class I / II operations as Class III in 18-24 months — the experience must be genuine and documented.

Supply chain complexity: the medical device global supply chain that PE buyers obsess over

Medical device manufacturing supply chains are uniquely complex and PE buyers diligence them more rigorously than any other manufacturing sub-vertical. Medical device materials (polymers, metals, electronics, biocompatible coatings, sterile packaging) require qualified-supplier relationships, FDA-registered material sources, biocompatibility documentation per ISO 10993, supplier audit history, and material traceability. Many materials are sole-sourced from specific qualified suppliers because re-qualifying alternative suppliers requires biocompatibility re-testing, FDA notifications, and customer requalification.

Supplier qualification and material traceability. Buyers diligence: complete supplier list with qualification status (qualified, conditionally qualified, unqualified); material traceability documentation by lot for biocompatibility-relevant materials; FDA-registered material source documentation; supplier audit history for top 10 suppliers; supplier change history (any material or supplier changes in past 3 years require regulatory review); China / Asia exposure (post-pandemic supply chain repositioning has made China / Asia material exposure a real diligence flag); single-sourced materials with no qualified backup.

Cleanroom and controlled-environment infrastructure. Class II disposable manufacturing typically requires ISO Class 7 or Class 8 cleanroom (10,000-100,000 particles per cubic foot at 0.5 microns). Class III implantable manufacturing typically requires ISO Class 5 or Class 7 cleanroom for terminally-sterilized implants. Cleanroom infrastructure investment $200K-$3M+ per cleanroom, with HVAC, monitoring, gowning, and validation overhead. Buyers diligence cleanroom classification documentation, monitoring history, and validation status.

Sterilization validation and process controls. Most Class II and Class III medical devices require terminal sterilization. Common modalities: ethylene oxide (EtO — subject to evolving EPA regulation), gamma irradiation, e-beam, steam autoclave for non-thermal-sensitive devices. Sterilization validation per ISO 11135 (EtO), ISO 11137 (irradiation), ISO 17665 (steam) is required. Process controls and continuous monitoring documentation. The 2024-2025 EPA regulatory shifts on EtO have made sterilization validation a real diligence focus.

Reshoring incentives and supply chain repositioning. Inflation Reduction Act, CHIPS and Science Act, and post-pandemic supply chain security concerns have created reshoring incentives for medical device manufacturing. PE buyers increasingly value U.S.-domestic supply chain depth as a thesis. Contract manufacturers with U.S.-domestic material sources and reduced China / Asia exposure trade at premium relative to those with significant Asian supply chain exposure.

What medical device manufacturing buyers diligence: the checklist that determines your final price

Medical device manufacturing diligence is the most demanding in any lower middle market manufacturing M&A. Buyers want to verify earnings, validate regulatory scope and FDA inspection history, confirm customer relationships and validated programs, assess equipment fleet and cleanroom infrastructure, dissect customer concentration and program portfolio, evaluate workforce continuity, and identify product liability, supply chain, and successor liability exposure.

Earnings quality and program-level cost analysis. 24-36 months of monthly P&Ls. Job costing by program / customer / part number. Standard cost variance analysis. Material cost reconciliation. Add-back documentation. CPA-prepared financial statements. Bank reconciliations. AR aging. Inventory accounting (raw material with material certifications, WIP, finished goods, sterile-stored finished goods). Program-level margin analysis.

Regulatory scope and FDA inspection history. ISO 13485 certification documentation with surveillance audit reports (last 3 years). FDA establishment registration. FDA 21 CFR 820 QSR documentation: design controls, DMR by device, DHF by program, CAPA log, complaint log, MDR (Medical Device Reporting) log, recall history. FDA inspection history with every Form 483 observation in past 5 years, every Warning Letter, every CAPA opened in response. Customer audit results (Medtronic supplier audit, J&J supplier audit, Stryker supplier audit, etc.). Notified body audit history if EU MDR. ISO 14971 risk management documentation. Sterilization validation per ISO 11135 / 11137 / 17665.

Customer relationships and validated program portfolio. Top 10 customers as percentage of revenue 3-year history. Customer-by-customer program list with revenue, medical OEM end-product identification, validated-program tenure, FDA-registered tooling count, multi-year LTA terms, backlog visibility. Customer references the buyer can call. Customer-specific quality metrics (PPM, on-time delivery, supplier scorecards). Medical OEM supplier qualification status. Program lifecycle stage.

Equipment, cleanroom, and capex history. Cleanroom inventory with classification, square footage, monitoring history, validation status. Equipment inventory by department: precision injection molding (for medical molders), CNC machining (for surgical instrument manufacturers), sterile assembly stations, automation, vision systems, packaging lines, sterile packaging equipment. Sterilization equipment if in-house (EtO, steam, gamma; most outsource gamma). Inspection equipment: CMM, optical, vision systems. ERP / MES system. 5-year capex history.

Workforce continuity and skills. Skilled trades roster with age, tenure, certifications (ISO 13485 internal auditor, regulatory affairs, validation engineering, quality engineering, sterile manufacturing operations). Workforce concentration on key validated-program operators. Cross-training matrix. Compensation. Turnover history. Recruiting pipeline. Medical device skills (sterile operations, validated-process execution, quality mindset for FDA-regulated environment) take years to develop.

Supply chain, product liability, and successor liability. Complete supplier list with qualification status. Material traceability documentation. Single-sourced materials inventory. China / Asia exposure assessment. Active product liability exposure on installed devices. Recall history. MDR (Medical Device Report) submissions. Customer warranty exposure. Insurance coverage (medical device product liability has unique structure, often $10-50M coverage required by medical OEM customers). Environmental Phase I or Phase II if EtO sterilization or chemical processing on-site.

Medical device manufacturing sale process timeline: month-by-month

Medical device manufacturing sale processes typically run 11-15 months from launch to close — among the longest in lower middle market manufacturing due to regulatory diligence depth and customer interview rigor. Class III implantable manufacturers run toward the longer end (PMA-pathway diligence depth, FDA inspection history review). Combination device manufacturers similarly. Drug delivery contract manufacturers fall in similar range. Class I / II only manufacturers run more standard timelines. Public-company strategic acquirer timelines (Integer Holdings, West Pharmaceutical Services) include integration planning.

Months 1-2: positioning and outreach. Build the CIM (50-90 pages typical for medical device given regulatory, customer, and program-level documentation requirements). Position by Class tier, certification scope, and customer base. Reach out to medical device specialty PE platforms (Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax Group, Wynnchurch Capital industrial, Riverside Company, Genstar Capital, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe), Tier 1 medical contract manufacturer strategic acquirers (Integer Holdings, Phillips Medisize / Molex, West Pharmaceutical Services, Heraeus Medical, Resonetics, Cretex Medical, Nordson Medical, Carlisle Medical), direct medical OEM strategic acquirers for vertical integration opportunities, medical device regional consolidators, family offices with healthcare theses, search funders. Sign NDAs. Target 10-20 serious initial conversations.

Months 2-5: management meetings and IOIs. Medical device specialty PE and Tier 1 contract manufacturer strategics send 4-8 person teams (operating partners, regulatory experts, quality leaders, sector leads, deal team) for facility tours. Tours cover production floor, cleanroom areas (usually outside cleanroom looking in for confidentiality), quality lab, sterilization / packaging, validation, regulatory affairs offices, R&D / new product development if applicable. Receive 5-10 IOIs with non-binding price ranges. Negotiate to a single LOI.

Months 5-12: LOI, diligence, and definitive agreement. Sign LOI with 90-120 day exclusivity (longer than other sub-verticals given diligence depth). Buyer-side diligence includes financial QoE ($75-200K) with program-level cost analysis; operational QoE ($40-100K) covering equipment modernity, OEE, cleanroom utilization, capex history; commercial diligence (top 10 customer interviews, medical OEM reference calls); regulatory diligence (FDA establishment registration verification, FDA inspection history review, ISO 13485 audit review, EU MDR notified body audit review, customer audit history review — often by a regulatory consulting firm); environmental Phase I or Phase II for EtO sterilization or chemical processing operations; supply chain diligence (single-sourced material exposure, China / Asia exposure, material traceability documentation); workforce due diligence; insurance and product liability review (medical device product liability is unique structure).

Months 12-15: close and transition. Definitive agreement negotiation: working capital target (often material in medical device given long-cycle inventory and validation lots), indemnification caps, R&W insurance for $3M+ EBITDA deals (premium typically 2-5% of coverage; medical device R&W insurance is more expensive than other sub-verticals due to product liability exposure), non-compete (5-7 years for medical device), seller employment / consulting (12-36 months common to support FDA-inspection-relationship continuity and customer-relationship continuity), earnout structure (12-36 months tied to EBITDA milestones, customer retention, FDA inspection results, validated-program retention). FDA establishment registration update if applicable. ISO 13485 notification of ownership change to certifying body. EU MDR notified body notification if applicable. Customer notification per LTA terms. Final walkthrough. Employee notification. Escrow funding. Signing.

Common mistakes medical device manufacturing sellers make (and how to avoid them)

Mistake 1: positioning as a generic precision manufacturer when you have medical device specialty. If 50%+ of your revenue is medical and you have ISO 13485 + FDA 21 CFR 820 QSR-aligned operations, present yourself as a medical device contract manufacturer specialty. The medical-specialty positioning brings Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax, Wynnchurch Industrial, Riverside Company, plus Tier 1 medical contract manufacturer strategics (Integer Holdings, Phillips Medisize, West Pharmaceutical) into the deal — and they pay 3-5x EBITDA more than generic manufacturing buyers. The headline difference at $4M EBITDA is $12-20M of enterprise value.

Mistake 2: ignoring open FDA Form 483 observations or Warning Letters. Open FDA matters can re-trade or kill medical device deals. If you have outstanding Form 483 observations from a recent inspection, work with regulatory counsel to close them out fully (CAPA implementation + verification) before going to market. Warning Letters require months of remediation and FDA close-out. Don’t take a deal to LOI with open FDA matters — it will cost you 1-2x EBITDA in valuation.

Mistake 3: under-investing in design controls and DMR / DHF documentation depth. FDA 21 CFR 820 QSR requires design controls, DMR (device master record), and DHF (design history file) for each device. Many smaller medical device contract manufacturers have gaps in design control documentation, particularly for legacy devices. Buyers diligence this rigorously. Closing documentation gaps over 12-18 months pre-sale is the highest-ROI regulatory preparation investment.

Mistake 4: weak Class III experience documentation when you have it. Contract manufacturers with documented Class III implantable experience trade at 10-13x EBITDA. Many sellers under-document their Class III experience in CIMs, understating the regulatory moat. Build a program portfolio matrix that explicitly identifies Class III work, PMA-pathway customers, and the validation depth supporting that work.

Mistake 5: ignoring supply chain documentation in CIM. PE buyers and Tier 1 strategics increasingly diligence supply chain depth. China / Asia exposure is a 2026 diligence focus. Sellers who can document U.S.-domestic supply chain depth, qualified-supplier relationships, and reduced single-source exposure trade at premium. Build a supplier qualification and material-source documentation package as part of pre-sale preparation.

Mistake 6: aging cleanroom and equipment infrastructure without modernization. Cleanroom infrastructure beyond 12-15 years often shows monitoring and validation aging. Investing in cleanroom upgrades (HEPA replacement, monitoring system upgrades, lighting / energy efficiency) and 1-2 modern injection molding presses, machining centers, or assembly automation 18-24 months pre-sale shifts the equipment narrative and supports premium multiple.

Mistake 7: workforce-continuity risk without succession plan. Medical device skilled workforce (sterile operations, validated-process execution, regulatory affairs, quality engineering) takes years to develop and is scarce. If your operation depends on 2-3 senior regulatory or quality professionals without documented succession, buyers heavily discount. Build a documented succession plan with cross-training, named successors for critical regulatory and quality roles, and retention agreements.

How to position for the right medical device manufacturing buyer archetype

Position for medical device specialty PE platforms (Linden Capital, Patient Square, LaSalle, Audax, Wynnchurch Industrial, Riverside) when: You have $2M+ EBITDA, ISO 13485 + FDA 21 CFR 820 QSR-aligned operations, named medical OEM relationships, validated programs across multiple device tiers, clean FDA inspection history, modern cleanroom infrastructure, and willingness to roll equity 15-30%. Emphasize: regulatory scope and clean FDA history, named-OEM relationships, validated-program tenure, Class III experience if applicable, growth runway, and integration into broader medical device platform thesis.

Position for Tier 1 medical contract manufacturer strategic acquirers (Integer, Phillips Medisize, West Pharmaceutical, Heraeus, Resonetics, Cretex, Nordson, Carlisle) when: You have $3M+ EBITDA, specialty capability the Tier 1 doesn’t have (specific component category, specific customer relationship, specific manufacturing capability like micro-molding, electronic assembly, surgical instrument manufacturing, drug delivery), and willingness to integrate. Tier 1 strategics often pay 8-12x EBITDA at scale with cash-heavy structures.

Position for direct medical OEM strategic acquirers (Medtronic, J&J, Stryker, Boston Scientific, Abbott) when: You manufacture critical components for the OEM with vertical integration upside, hold key Class III device manufacturing capacity, or have IP / design capability the OEM wants to internalize. Direct OEM acquisitions are less frequent but command 9-13x EBITDA when synergies are clear.

Position for medical device regional consolidators when: You have $1M-$5M EBITDA, ISO 13485 + FDA 21 CFR 820 alignment, geographic fit with medical device clusters (Twin Cities, Boston, Southern California, North Carolina Research Triangle, Salt Lake City, Indiana), and willingness to roll equity. Regional consolidators value workforce continuity and validated-program portfolio depth.

Position for search funders, family offices, and SBA individuals when: You have $300K-$3M EBITDA, ISO 13485-certified, the business runs on documented systems, owner role is replaceable with 90-180 days of training, and customer base is manageable. Medical-experienced search funders and SBA buyers (former Medtronic, J&J, Stryker, BD program managers) are the strongest sub-segment of this archetype.

Tax planning for medical device manufacturing exits

Medical device manufacturing exits are typically structured as stock sales at $3M+ EBITDA (preserves ISO 13485 / FDA 21 CFR 820 / EU MDR registrations and customer LTAs) or asset sales below that threshold. Stock sales avoid the certification re-registration delay (asset sales often require new entity to re-establish FDA establishment registration, ISO 13485 certification, and customer audit acceptance, which can take 12-24 months). For Class III implantable manufacturers, stock sales are essentially mandatory for deal completion. For combination device manufacturers, stock sales preserve dual regulatory pathway continuity.

Typical asset allocation in a $5M EBITDA medical device sale at $42M EV. Tangible assets (cleanroom, equipment, inventory, AR): $7-12M, taxed as ordinary income recapture at up to 37% federal plus state. Goodwill: $28-35M, taxed as long-term capital gains at 23.8% federal plus state. Non-compete: $400K-$1.2M. Consulting / employment: $700K-$2.5M (especially when ISO 13485 / FDA 21 CFR 820 transition or customer-relationship continuity requires extended seller engagement).

Stock sale economics at platform scale. At $3M+ EBITDA platform-scale medical device deals, stock sales preserve full federal capital gains treatment (23.8% federal-only) on the entire purchase price. Buyers typically discount headline price 3-7% for the lost depreciation step-up (less than other sub-verticals because medical device equipment depreciation is less material relative to goodwill) but seller’s after-tax outcome is often better than asset-sale equivalent. Tax-attorney-driven transaction structuring matters at this scale.

Section 1202 QSBS for medical device C-corps held 5+ years. Section 1202 QSBS can exclude up to $10M of capital gains from federal tax for qualifying C-corp stock held 5+ years. The $50M aggregate gross asset test typically permits medical device shops up to $10-15M EBITDA scale. Many medical device family-owned C-corps qualify but the structure is rarely optimized. Talk to a tax attorney 18+ months before sale — QSBS can dramatically improve net-after-tax outcomes.

Rollover equity tax deferral. Rolling 20-30% of equity into a Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax, Wynnchurch Industrial, or Riverside Company medical device platform typically qualifies for tax-deferred treatment under Section 351 or 721. Medical device platforms have historically achieved strong exit multiples (10-14x EBITDA exit), making rollover economics particularly favorable. Linden Capital’s historical portfolio exit performance has been notably strong.

State tax considerations. Texas (medical device cluster including Houston Medical Center, Dallas, Austin), Florida (Miami medical device, Tampa cluster), Tennessee (Nashville medical device), Nevada, Wyoming offer 0% state capital gains. Major medical device states with state tax: Minnesota (Twin Cities medical device alley with Medtronic, Boston Scientific, 3M Health Care), Massachusetts (Boston medical device cluster including Boston Scientific, Edwards Lifesciences, Smith & Nephew), California (Stryker Endoscopy Acquisitions, Edwards Lifesciences, Abbott, Becton Dickinson), Indiana (Zimmer Biomet, Cook Medical, Roche Diagnostics), Utah (Salt Lake City medical device cluster). On a $42M sale, state-tax differential can be $2-4M.

When to wait: signals that delaying 18-36 months pays off

Medical device manufacturing preparation leverage is the highest in any manufacturing sub-vertical because the regulatory framework, customer-base development, validated-program depth, and skilled workforce all compound over multi-year horizons. The longer preparation horizon (24-36 months versus 18-24 in most sub-verticals) means the wait is meaningful. But the multiple impact is also the largest of any sub-vertical — often 4-6x EBITDA between unprepared and well-prepared positioning.

Signal 1: you serve medical OEMs without ISO 13485. If 30%+ of your revenue is medical without ISO 13485, achieving certification 18-24 months pre-sale is the highest-leverage move in lower middle market manufacturing. The certification cost ($50-150K) typically returns 8-15x in valuation through specialty multiple uplift (7-9x EBITDA versus 4-5x for generic precision manufacturing). On $2.5M EBITDA, the differential is $7.5-12.5M of additional pre-tax proceeds.

Signal 2: you have open FDA Form 483 observations or Warning Letters. Closing out open FDA matters is non-negotiable before going to market. Work with regulatory counsel to fully close CAPA actions, document corrections, and communicate completion to FDA. 6-12 months of focused regulatory closeout work often saves 1-2x EBITDA in valuation.

Signal 3: weak DMR / DHF / design controls documentation. FDA 21 CFR 820 QSR documentation depth is buyer-diligence-critical. 12-18 months of focused documentation closeout (DMR completion for each device, DHF retroactive documentation where possible, design controls audit and gap closure, CAPA system maturity) supports premium multiple positioning.

Signal 4: Class III experience exists but isn’t documented in CIM. Many medical device contract manufacturers have done Class III work but don’t systematically document it. Building a program portfolio matrix that explicitly identifies Class III experience, PMA-pathway customers, validation depth, and biocompatibility testing scope supports premium-tier positioning (10-13x EBITDA for documented Class III specialists).

Signal 5: aging cleanroom and equipment infrastructure. Investing in cleanroom upgrades and 1-2 modern equipment installations (precision injection molding, complex CNC machining, automation, vision systems) 18-24 months pre-sale shifts the equipment narrative and adds 0.5-1x EBITDA in valuation.

Signal 6: supply chain exposure (China / Asia) without diversification. Reducing China / Asia material exposure through qualified-alternative-supplier development over 12-18 months addresses a 2026 PE buyer diligence focus and supports premium multiple. Reshoring incentives (Inflation Reduction Act, CHIPS Act) make this an increasingly important value driver.

When NOT to wait. Health forcing exit. Co-owner conflict. Personal financial liquidity needs. Specific medical OEM customer signaling re-sourcing or program risk. PE / Tier 1 strategic activity slowing in your specific sub-segment. Open FDA matter that’s not closeable on reasonable timeline (in this case, accept the multiple compression and price expectations accordingly).

Earnouts, rollover equity, and seller financing in medical device manufacturing deals

Medical device manufacturing deals at $1M+ EBITDA almost always include some combination of earnout, rollover equity, and seller financing. Medical device specialty PE platforms (Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax, Wynnchurch Industrial, Riverside Company) structure deals with cash + 15-30% rollover + 18-36 month earnout. Tier 1 contract manufacturer strategics (Integer Holdings, Phillips Medisize, West Pharmaceutical) typically pay more cash with smaller rollover and shorter earnouts. Direct medical OEM strategic deals (Medtronic, J&J, Stryker, etc.) typically pay cash-heavy with integration milestones.

Typical medical device specialty PE structure at $5M EBITDA / $45M EV (9x). Cash at close: $30-34M (67-76%). Rollover equity into the platform: $7-11M (16-24%). Earnout: $3-7M (7-16%) tied to EBITDA milestones, customer retention (especially top medical OEM relationships), FDA inspection results (no Form 483 observations during earnout period), and validated-program retention. Medical device earnout realization rates run 75-85% historically — among the highest in any manufacturing sub-vertical because revenue durability is structurally strong.

Tier 1 contract manufacturer strategic structures. Integer Holdings, Phillips Medisize, West Pharmaceutical Services, Heraeus Medical, Resonetics, and Cretex Medical typically structure deals 80-90% cash with smaller rollover (often via stock of the public company itself for public Tier 1s like Integer and West) and shorter earnouts (12-18 months). The benefit: more cash certainty, public company stock optionality where applicable. The trade-off: lower upside than rolling into a PE platform with a 4-5 year exit horizon at higher exit multiples.

Rollover equity into medical device specialty PE platforms. Rolling 20-30% into a Linden Capital, Patient Square, LaSalle, Audax, Wynnchurch Industrial, or Riverside Company medical device platform creates exposure to platform exit (typically 4-5 years to a larger PE, Tier 1 strategic, or sometimes IPO). Medical device platforms have historically achieved strong exit multiples (10-14x EBITDA exit), with rollover economics typically delivering 2.5-3.5x money-on-money over the hold period. Linden Capital’s portfolio has notably strong historical exit performance.

SBA seller-financing for sub-$1M medical device shops. SBA 7(a) loans capped at $5M total project. Buyer equity 10% minimum. Seller note 20-30% of purchase price, subordinated, on standby for 24+ months. Medical device SBA buyers are typically industry-experienced (former Medtronic, J&J, Stryker, BD, Boston Scientific program managers, regulatory affairs professionals, or quality engineers) which improves outcomes versus generic SBA buyers. The regulatory complexity of medical device makes industry-experienced SBA buyers particularly important.

Conclusion

Selling a medical device manufacturing business in 2026 is the highest-multiple opportunity in lower middle market manufacturing M&A — with structural tailwinds from demographic aging, drug delivery / combination device growth, surgical robotics expansion, and reshoring incentives. But the multiples and outcomes diverge dramatically based on regulatory scope (ISO 13485, FDA 21 CFR 820 QSR, 510(k) vs PMA pathway, EU MDR, ISO 14971, ISO 10993), Class I/II/III device tier mix, named medical OEM customer relationships (Medtronic, Johnson & Johnson MedTech, Stryker, Boston Scientific, Abbott, BD, Edwards Lifesciences, Zimmer Biomet, Thermo Fisher), validated-program portfolio depth, FDA inspection history, supply chain documentation, cleanroom and equipment infrastructure, and skilled workforce continuity. Owners who succeed are the ones who stop benchmarking against generic precision-manufacturing multiples and start benchmarking against the actual 2026 medical device buyer pool: medical device specialty PE platforms (Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax Group, Wynnchurch Capital industrial, Riverside Company, Genstar Capital, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe) paying 8-12x EBITDA on platforms (10-13x for Class III implantable specialists), Tier 1 medical contract manufacturer strategics (Integer Holdings, Phillips Medisize, West Pharmaceutical Services, Heraeus Medical, Resonetics, Cretex Medical, Nordson Medical, Carlisle Medical) paying 8-12x EBITDA at platform scale, direct medical OEM strategics paying 9-13x EBITDA on vertical integration synergies, regional consolidators paying 7-9x EBITDA on bolt-ons, search funders and family offices paying 6-8x EBITDA for $1M-$3M EBITDA targets, and SBA buyers paying 5-7x SDE on sub-$1M ISO 13485 shops. Get your books clean and program-level documented 18-24 months ahead. Build the regulatory stack (ISO 13485, FDA 21 CFR 820 QSR depth, EU MDR if European exposure) over 24-36 months. Close out any open FDA matters before going to market. Document Class III experience explicitly. Modernize cleanroom and equipment infrastructure. Build supply chain documentation and reduce China / Asia exposure. Build workforce-continuity story for regulatory and quality professionals. Position for the right buyer archetype rather than running a generic auction. The owners who do this work see 50-100% better after-tax outcomes than the ones who go to market unprepared. And if you want to talk to someone who already knows the medical device buyers personally instead of running an auction, we’re a buy-side partner — the buyers pay us, not you, no contract required.

Frequently Asked Questions

What multiple should I expect when selling my medical device manufacturing business in 2026?

Sub-$1M SDE medical contract mfr (no ISO 13485): 4-5.5x SDE. Sub-$1M SDE ISO 13485 medical contract mfr: 5-7x SDE. $1M-$3M EBITDA ISO 13485 + FDA-aligned: 7-9x EBITDA. $3M+ EBITDA Class II disposables specialist: 8-10x EBITDA. $3M+ EBITDA Class III implantable specialist: 10-13x EBITDA. Drug delivery / combination devices: 9-12x EBITDA. Medical device commands the highest multiples in lower middle market manufacturing.

Who are the most active PE buyers of medical device manufacturing businesses right now?

Linden Capital Partners (most active dedicated medical device PE in U.S. with multiple platforms), Patient Square Capital (medical device thesis), LaSalle Capital, Audax Group (medical / industrial), Wynnchurch Capital industrial (medical adjacencies), Riverside Company medical specialty, Genstar Capital medical, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe medical, plus 15+ medical device consolidators. Tier 1 medical contract manufacturer strategics include Integer Holdings (NYSE: ITGR), Phillips Medisize / Molex / Koch, West Pharmaceutical Services (NYSE: WST), Heraeus Medical, Resonetics, Cretex Medical, Nordson Medical, Carlisle Medical.

How does ISO 13485 certification affect my sale?

Materially. ISO 13485 is the medical device QMS baseline required for medical OEM contract manufacturing. Achieving certification typically takes 12-18 months and costs $50-150K. The multiple impact: medical device specialty PE platforms (Linden Capital, Patient Square, LaSalle, Audax, Wynnchurch Industrial, Riverside) and Tier 1 strategics (Integer, Phillips Medisize, West) won’t engage without ISO 13485 + FDA 21 CFR 820 QSR alignment. Going from generic precision manufacturer (4-5x EBITDA) to medical specialty (8-12x EBITDA) typically returns 8-15x the certification cost in valuation.

What is FDA 21 CFR 820 QSR and how does it relate to ISO 13485?

FDA 21 CFR Part 820 (Quality System Regulation, QSR) is the U.S. federal regulation governing medical device manufacturers. It largely overlaps with ISO 13485 but is technically distinct. Key requirements: design controls, DMR (device master record), DHF (design history file), CAPA (corrective and preventive action) system, complaint handling, MDR (Medical Device Reporting). ISO 13485 certification doesn’t fully satisfy FDA 21 CFR 820 — FDA inspections can find gaps even at ISO 13485-certified facilities. Buyers diligence both ISO 13485 audit history AND FDA inspection history.

How do Class I/II/III device tiers affect my multiple?

Materially. Class I-only generic medical contract mfrs trade at 6-8x EBITDA. Class I + II contract mfrs (the largest segment, including surgical instruments, infusion, drug delivery non-combination, diagnostic disposables, hospital beds) trade at 7-9x EBITDA. Class III implantable specialists (orthopedic, cardiovascular, neurological implants for Stryker / Zimmer Biomet / Medtronic / Abbott / Boston Scientific / Edwards Lifesciences) trade at 10-13x EBITDA. Combination devices and drug delivery (auto-injectors, on-body devices) trade at 9-12x EBITDA. Class III experience is genuinely scarce.

What is the difference between 510(k) and PMA pathway?

510(k) is FDA’s substantial equivalence pathway for Class II devices — demonstrating equivalence to a previously cleared device. Faster, cheaper, lower regulatory complexity. PMA (Premarket Approval) is FDA’s most rigorous pathway for Class III devices — requires clinical data, design controls per 21 CFR 820.30, biocompatibility per ISO 10993, and process validation. Contract manufacturers with PMA-pathway experience are scarce because the workforce, equipment, and quality system requirements take 5-10 years to build. PMA-experienced contract mfrs trade at premium.

How does FDA inspection history affect my sale?

Critically. Open FDA Form 483 observations or unresolved Warning Letters can re-trade or kill medical device deals. Buyers diligence every Form 483 observation in past 5 years, every Warning Letter, every CAPA opened in response, every regulatory commitment to FDA. Closing out open FDA matters fully (CAPA implementation + verification + FDA close-out) is non-negotiable before going to market. Maintaining clean inspection history through close is essential.

How does customer concentration work in medical device contract manufacturing?

Customer concentration above 30-40% on a single medical OEM (Medtronic, J&J MedTech, Stryker, Boston Scientific, Abbott, BD, Edwards Lifesciences, Zimmer Biomet) is common and not necessarily a discount driver if the program portfolio with that customer is diversified across multiple devices and validated programs are long-tenured. Medical OEM switching cost is genuinely high (re-validation, FDA notifications, supplier requalification, biocompatibility re-testing) so concentrated relationships often endure 10-20 years. Buyers price concentration based on program-level diversification and validated-program tenure.

What about supply chain and China / Asia exposure?

Supply chain documentation is a 2026 PE buyer diligence focus. Reshoring incentives (Inflation Reduction Act, CHIPS Act) and post-pandemic supply chain security concerns make U.S.-domestic supply chain depth a real value driver. Buyers diligence: supplier qualification status, material traceability documentation, single-sourced material exposure, China / Asia exposure assessment, supplier audit history. Reducing Asian supply chain exposure 12-18 months pre-sale supports premium multiple.

How long does it take to sell a medical device manufacturing business?

11-15 months from launch to close typical — among the longest in lower middle market manufacturing due to regulatory diligence depth and customer interview rigor. Class III implantable manufacturers and combination device manufacturers run toward the longer end. Class I / II only manufacturers run more standard timelines. Add 24-36 months on the front for proper preparation if ISO 13485, FDA 21 CFR 820 QSR depth, customer relationships, cleanroom infrastructure, supply chain, and workforce continuity aren’t buyer-ready.

Should I structure as a stock sale or asset sale?

Stock sales are strongly preferred at $3M+ EBITDA platform-scale medical device deals because they preserve ISO 13485 / FDA 21 CFR 820 / EU MDR registrations, FDA establishment registration, and customer LTAs. Asset sales often require new entity to re-establish FDA registration, ISO 13485 certification, and customer audit acceptance — which can take 12-24 months and is essentially a deal-killer for Class III implantable manufacturers and combination device manufacturers. Stock sales also preserve full federal capital gains treatment (23.8% federal-only).

Should I sell now or wait for the next medical device cycle?

Generally now. Medical device 2026 has unprecedented structural tailwinds: demographic aging driving sustained orthopedic / cardiovascular / chronic disease management demand, drug delivery (auto-injectors, GLP-1 driven semaglutide / tirzepatide demand) the fastest-growing segment, surgical robotics adoption (Intuitive Surgical, Medtronic Hugo, Stryker Mako, J&J Velys), reshoring incentives. PE buyers and Tier 1 strategics are competing for platform deals at the highest multiples in any manufacturing sub-vertical. The buyer pool may not stay this competitive indefinitely — if you’re within 18-24 months of the right preparation, capturing this market is more likely to outperform waiting through cycle uncertainty.

How is CT Acquisitions different from a sell-side broker or M&A advisor?

We’re a buy-side partner, not a sell-side broker. Sell-side brokers represent you and charge you 5-10% of the deal (often $2M-$8M+ on platform-scale medical device deals) plus monthly retainers, run an 11-15 month auction process, and require 12-month exclusivity. We work directly with 76+ buyers — including 38 manufacturing-focused platforms covering medical device manufacturing (medical device specialty PE like Linden Capital Partners, Patient Square Capital, LaSalle Capital, Audax Group, Wynnchurch Capital industrial, Riverside Company, Genstar Capital, Frazier Healthcare Partners, Welsh Carson Anderson & Stowe; Tier 1 medical contract manufacturer strategics like Integer Holdings, Phillips Medisize, West Pharmaceutical Services, Heraeus Medical, Resonetics, Cretex Medical, Nordson Medical, Carlisle Medical; direct medical OEM strategics; family offices with healthcare theses; medical-experienced search funders) — who pay us when a deal closes. You pay nothing. No retainer, no exclusivity, no contract until a buyer is at the closing table. We move faster (90-150 days from intro to close at platform scale) because we already know which medical device buyer fits your specific certification scope, device tier mix, and customer base rather than running a generic auction to find one.

Sources & References

All claims and figures in this analysis are sourced from the publicly available references below.

1. FDA 21 CFR Part 820 Quality System Regulation — FDA 21 CFR Part 820 (Quality System Regulation, QSR) defines design controls, DMR, DHF, CAPA, complaint handling, and MDR requirements for medical device manufacturers.
2. ISO 13485:2016 Medical Devices QMS Standard — ISO 13485 is the international quality management system standard for medical device design, manufacture, and post-market surveillance — the regulatory baseline for medical device contract manufacturers.
3. FDA 510(k) Premarket Notification — 510(k) substantial equivalence pathway is the FDA premarket clearance route for most Class II medical devices.
4. FDA Premarket Approval (PMA) — PMA (Premarket Approval) is FDA’s most rigorous regulatory pathway, required for Class III medical devices including implantables.
5. Linden Capital Partners — Linden Capital Partners is a healthcare-focused PE firm with multiple medical device manufacturing platform investments across contract manufacturing, components, and specialty medical.
6. Integer Holdings — Integer Holdings (NYSE: ITGR) is among the largest Tier 1 medical device contract manufacturers in the U.S., actively acquiring smaller medical device manufacturers.
7. U.S. Small Business Administration (SBA) 7(a) Loan Program — SBA 7(a) loans cap at $5M total project value — the financing source for sub-$1M medical device contract manufacturer acquisitions by individual buyers.
8. EU Medical Device Regulation (EU 2017/745) — EU MDR governs medical device market access in the European Union and overlays additional regulatory requirements on top of ISO 13485 and FDA 21 CFR 820.